Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Hepatoblastoma

Hepatoblastoma

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hepatoblastoma

3 trials tracked for Hepatoblastoma.

3Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 3
  1. Phase 2 A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB Completed
  2. Phase 2 Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed
  3. Phase 2 Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Completed

Showing the 3 most-cited and recently-updated of 3 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
AKR1B10 may serve as a serum biomarker for AFP-negative hepatoblastoma subtypes
Rheumatology Sys. Review
AKR1B10 may serve as a serum biomarker for AFP-negative hepatoblastoma subtypes Scientists Explore Blood Marker Idea for Childhood Liver Cancer
This narrative review explores the potential of Aldo-keto reductase 1B10 (AKR1B10) as a biomarker for pediatric liver tumors. The authors su…
A new review suggests a protein called AKR1B10 might one day help spot some childhood liver cancers, but no patient data exist yet.
Frontiers Oct 23, 2026